Pfizer’s GLP-1 Drug Shows Sustained Weight Loss with Monthly Dosing in Phase 2b Trial
Event summary
- Pfizer’s Phase 2b VESPER-3 study showed up to 12.3% placebo-adjusted weight loss at week 28 with monthly dosing of PF’3944.
- The study demonstrated continued weight loss without plateau after switching from weekly to monthly injections.
- PF’3944 maintained a favorable safety profile with no severe gastrointestinal adverse events reported.
- Pfizer plans to include a higher 9.6 mg monthly dose in Phase 3 trials based on the study results.
The big picture
Pfizer’s positive Phase 2b results for PF’3944 reinforce its position in the competitive obesity treatment market. The shift to monthly dosing could enhance patient compliance and differentiate the drug from weekly alternatives. With plans for multiple Phase 3 trials, Pfizer is positioning itself to address critical gaps in obesity care, leveraging its expanded pipeline post-acquisition of Metsera and collaboration with YaoPharma.
What we're watching
- Phase 3 Strategy
- Whether Pfizer’s plan to include a higher 9.6 mg monthly dose in Phase 3 will maintain efficacy and safety.
- Pipeline Expansion
- The pace at which Pfizer advances its 20+ planned obesity trials in 2026.
- Market Positioning
- How Pfizer’s diverse obesity pipeline will compete with existing GLP-1 treatments.
Related topics